# US 2013/0252997 A1 · Treating unwanted ocular condition using an ascomycin macrolactam

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252997 A1
- Document ID: US20130252997A1
- Status: Published application
- Kind: A1
- Application number: 13/887,057
- Filed: 2013-05-03
- Published: 2013-09-26
- Earliest claimed: 2007-01-30
- Assignees: Allergan, Inc.
- Applicants: Allergan, Inc.
- Inventors: Rhett M. Schiffman
- Web page: https://patentgrep.com/patent/US20130252997A1

## CPC

- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/4353: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 38/212: {IFN-alpha}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 27/02: Ophthalmic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides compositions and uses of an ascomycin macrolactam for the treatment of an unwanted ocular condition occurring in a patient undergoing treatment with a therapeutically active agent for the treatment of cancer.

## Claims

### Claim 1

A method for treating an unwanted ocular condition occurring in a patient undergoing cancer treatment with a therapeutically active agent effective for treatment of a cancer, the method comprising the step of administering an effective amount of an ascomycin macrolactam to the patient, wherein the ascomycin macrolactam administration reduces a symptom of the ocular condition associated with the use of said therapeutically active agent effective for treatment of a cancer, wherein the ascomycin macrolactam is tacrolimus, pimecrolimus, ascomycin, or any combination thereof, and wherein the unwanted ocular condition is nasolacrimal stenosis, canalicular stenosis, lacrimal duct stenosis, chemotherapy induced ocular toxicity, lacrimation, abnormal lacrimation, epiphora, nasolacrimal blockage, dacryocystitis, or keratitis.

### Claim 2 (depends on 1)

The method of claim 1, wherein the ascomycin macrolactam is administered before administration of the therapeutically active agent.

### Claim 3 (depends on 1)

The method of claim 1, wherein the ascomycin macrolactam is administered after administration of the therapeutically active agent.

### Claim 4 (depends on 1)

The method of claim 1, wherein the ascomycin macrolactam is administered simultaneously with administration of the therapeutically active agent.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The method of claim 1, wherein the therapeutically active agent is a chemotherapy agent.

### Claim 7 (depends on 6)

The method of claim 6, wherein the chemotherapy agent is Paclitaxel or a Paclitaxel derivative.

### Claim 8 (depends on 6)

The method of claim 6, wherein the chemotherapy agent is selected from the group consisting of Docetaxel, Doxorubicin Hydrochloride, Irinotecan Hydrochloride, Fluorouracil, Imatinib Mesylate, and Rituximab.

### Claim 9 (depends on 8)

The method of claim 8, wherein the chemotherapy agent is docetaxel.

### Claim 10 (depends on 1)

The method of claim 1, wherein the therapeutically active agent is an antiviral agent.

### Claim 11 (depends on 10)

The method of claim 10, wherein the antiviral agent is Zalcitabine, Rimantadine Hydrochloride, or any combination thereof.

### Claim 12 (depends on 1)

The method of claim 1, wherein the therapeutically active agent is an immunomodulator.

### Claim 13 (depends on 12)

The method of claim 12, wherein the immunomodulator is Interferon alfa-2b, Recombinant Mycophenolate Mofetil, Mycophenolate Mofetil Hydrochloride, or any combination thereof.

### Claim 14

(canceled)
